Kraig Biocraft Laboratories Announces the Successful Creation of New Commercial Hybrid Transgenic Silkworms
May 31 2011 - 6:05AM
Marketwired
Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that
it successfully mated its transgenic silkworms, which produce
recombinant spider silk, with a physically larger commercial strain
of the domesticated silkworm. The resulting hybrid silkworms are
larger than Kraig's original transgenic silkworms and are also
producing significantly larger recombinant silk cocoons.
Independent laboratory testing confirmed that the
transgenic/commercial silkworm hybrids are producing silk which is
significantly stronger and more flexible than that of the original
commercial strain. The new recombinant spider silk is a composite
silk composed of both native silkworm silk proteins and spider silk
proteins (as in the original Kraig transgenic silkworm whose
development was announced in late September).
Kim Thompson, the Company's CEO and Founder, stated, "The new
hybrid was specifically designed for commercialization and has been
designated 'Monster Hybrid,' which is the successful cross between
our transgenic silkworms and a much larger commercial strain.
"The result is a large, robust, commercial sized silkworm which
spins a larger commercial sized cocoon composed of recombinant
spider silk like the original transgenic. The new hybrid was
specifically designed to generate greater recombinant silk
production capacity than our original first generation
transgenic."
"This larger hybrid transgenic will be the platform for our
commercialization ramp up," Thompson continued. "Now that the
strength and elasticity qualities have been confirmed, we can move
forward with cultivating the hybrids in commercially viable
quantities. We are working diligently to increase our stock of the
new strain in order to increase our production capacity."
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories is a fully reporting biotechnology
company that recently achieved a series of scientific
breakthroughs, with implications for the global textile industry.
For further information please visit www.KraigLabs.com.
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "hopes," "develops," "researching," "research,"
"potential," "could" or other words or phrases of similar import.
Similarly, statements in this release that describe the Company's
business strategy, outlook, objectives, plans, intentions or goals
should all be considered forward-looking statements. All such
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those in forward-looking statements. Management cautions that
its ability to further its research, and create commercially-viable
products may be affected by the competitive environment, the
Company's financial condition and its ability to raise sufficient
capital to meet the financial obligations of its business plan and
to fund its continuing operations.
Contact: Ben Hansel (720) 288-8495
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024